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Regular blood transfusions from an early age are an
essential therapy for patients with b-thalassaemia major in
order to achieve optimal growth and adequate organ func-
tion, as well as to improve survival. As the human body
cannot excrete excess iron, regularly transfused patients
with b-thalassaemia will accumulate toxic, and eventually
lethal levels of iron in the body. For more than 40 yr, def-
eroxamine (Desferal
 ; Novartis Pharma AG, Basel, Swit-
zerland) has been the established chelation therapy for
iron-overloaded patients, however the demanding infusion
regimen often results in poor patient compliance.(1–3)
Deferiprone (Ferriprox
 ; Apotex Inc., Toronto, ON,
Canada) is a three-times daily, oral iron chelator that is
available as a second-line therapy for b-thalassaemia
Abstract
Objective: Many patients with transfusional iron overload are at risk for progressive organ dysfunction and
early death and poor compliance with older chelation therapies is believed to be a major contributing fac-
tor. Phase II⁄III studies have shown that oral deferasirox 20–30 mg⁄kg⁄d reduces iron burden, depending
on transfusional iron intake. Methods: The prospective, open-label, 1-yr ESCALATOR study in the Middle
East was designed to evaluate once-daily deferasirox in patients ‡2 yr with b-thalassaemia major and iron
overload who were previously chelated with deferoxamine and⁄or deferiprone. Most patients began treat-
ment with deferasirox 20 mg⁄kg⁄d; doses were adjusted in response to markers of over- or under-chela-
tion. The primary endpoint was treatment success, deﬁned as a reduction in liver iron concentration (LIC)
of ‡3m gF e⁄g dry weight (dw) if baseline LIC was ‡10 mg Fe⁄g dw, or ﬁnal LIC of 1–7 mg Fe⁄g dw for
patients with baseline LIC of 2 to <10 mg Fe⁄g dw. Results: Overall, 233⁄237 enrolled patients completed
1 yr’s treatment. Mean baseline LIC was 18.0 ± 9.1 mg Fe⁄g dw, while median serum ferritin was
3356 ng⁄mL. After 1 yr’s deferasirox treatment, the intent-to-treat population experienced a signiﬁcant
treatment success rate of 57.0% (P = 0.016) and a mean reduction in LIC of 3.4 mg Fe⁄g dw. Changes in
serum ferritin appeared to parallel dose increases at around 24 wk. Most patients (78.1%) underwent dose
increases above 20 mg⁄kg⁄d, primarily to 30 mg⁄kg⁄d. Drug-related adverse events were mostly mild to
moderate and resolved without discontinuing treatment. Conclusions: The results of the ESCALATOR
study in primarily heavily iron-overloaded patients conﬁrm previous observations in patients with b-thalas-
saemia, highlighting the importance of timely deferasirox dose adjustments based on serum ferritin levels
and transfusional iron intake to ensure patients achieve their therapeutic goal of maintenance or reduction
in iron burden.
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or inadequate. Despite the availability of these chelating
agents, some heavily transfused patients are unable to
achieve successful iron chelation.
There remains a need for an effective and tolerable
iron chelator with a less-demanding treatment schedule,
which may help ensure long-term compliance in regularly
transfused patients of all ages. Deferasirox is a once-
daily, oral iron chelator approved for the treatment of
transfusional iron overload in adult and paediatric
patients. The efﬁcacy and safety of deferasirox in
patients with a variety of transfusion-dependent anae-
mias was established during ﬁve 1-yr Phase II⁄III clinical
registration trials involving more than 1000 patients (4–
8). The efﬁcacy of deferasirox was monitored based on
the monthly assessment of serum ferritin levels, which is
the most widely used method for assessing body iron
burden as it is convenient, relatively inexpensive and eas-
ily reproducible. As serum ferritin levels can be affected
by factors such as inﬂammation (9) individual measure-
ments should be interpreted with caution; however, serial
measurements have been shown to be reliable for moni-
toring body iron burden. The deferasirox clinical trials
demonstrated that the efﬁcacy of treatment is dependent
on dose, which should be tailored to the degree of iron
burden and transfusional iron intake (10).
There is considerable evidence that iron burden should
be closely monitored and an effective and tolerable long-
term chelation therapy used in heavily transfused
patients from an early age. The ESCALATOR trial was
initiated to evaluate the efﬁcacy and safety of deferasirox
exclusively in regularly transfused patients with b-thalas-
saemia who had previously received deferoxamine and⁄or
deferiprone therapy.
Methods
Inclusion criteria
Male or female patients (‡2 yr) with b-thalassaemia and
transfusional iron overload were eligible for inclusion in
the study if they had been treated with prior mono- or
combination therapy with deferoxamine and⁄or deferi-
prone but had experienced unacceptable toxicity to defe-
roxamine, had poor response despite proper compliance
with deferoxamine, had documented non-compliance of
taking <50% of prescribed deferoxamine doses in the
previous year or if deferoxamine treatment was contrain-
dicated. Patients were also required to have a liver iron
concentration (LIC) of ‡2m gF e⁄g dry weight (dw) and
a serum ferritin level of ‡500 ng⁄mL. Paediatric patients
have to be of adequate weight (9.4 kg in patients who
received 20 mg⁄kg⁄d) to receive the smallest tablet of
deferasirox.
Patients were excluded from the study if they had a
mean alanine aminotransferase >300 U⁄L; serum creati-
nine above the upper limit of normal (ULN); signiﬁcant
proteinuria; uncontrolled hypertension; chronic hepatitis
B or active hepatitis C receiving speciﬁc treatment; and a
history of nephrotic syndrome, systemic diseases (cardio-
vascular, renal, hepatic) or any medical condition that
may have affected absorption, distribution, metabolism
or excretion of deferasirox. Patients were also excluded if
they had been treated with any investigational drugs
within the past 4 wk, or had a history of drug or alcohol
abuse within the past 12 months or a history of non-
compliance either with treatment or the protocol (e.g.
patients who were considered potentially unreliable
and⁄or not cooperative).
Institutional Review Board or Ethics Committee
approval was obtained at each participating institution.
All patients (or parents⁄guardians) provided written
informed consent. The study was conducted in accor-
dance with Good Clinical Practice guidelines and the
Declaration of Helsinki.
Study design
The ESCALATOR trial was a prospective, open-label, 1-
yr, multicentre study conducted between June 2004 and
November 2006 in seven thalassaemia treatment centres
in the Middle East; data reported in this paper are based
on patients from six sites. Patients were screened during
a 56-d run-in period for eligibility criteria, and a baseline
LIC was determined by liver biopsy. Patients previously
receiving deferiprone discontinued treatment at least 28 d
before receiving the ﬁrst dose of study medication.
Patients were permitted to receive deferoxamine until the
day before they entered the study.
The initial protocol stated that patients should receive
a deferasirox starting dose of 10 or 20 mg⁄kg⁄d, accord-
ing to baseline LIC and serum ferritin. However, based
on evidence from ongoing clinical trials indicating that
10 mg⁄kg⁄d was insufﬁcient in heavily iron-overloaded
patients, a subsequent protocol amendment introduced a
ﬁxed starting dose of 20 mg⁄kg⁄d. Routine dose adjust-
ments were performed in response to markers of over- or
under-chelation. Doses were increased based on serum
ferritin trends (rises of ‡1000 ng⁄mL on two consecutive
visits or >2500 ng⁄mL without decreasing trend) and
reduced for elevated levels of serum creatinine, urinary
protein : creatinine ratio and transaminases, and in
response to adverse events such as skin rashes. Dose
adjustments were performed in steps of 5 or 10 mg⁄kg⁄d,
within a range of 0–30 mg⁄kg⁄d. If serum ferritin levels
fell to £500 ng⁄mL at two consecutive study visits, defer-
asirox dose was withheld and resumed if serum ferritin
rose to >1000 ng⁄mL. The transfusion goals of the
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which was consistent from country to country.
Efﬁcacy assessments
The primary objective of the ESCALATOR study was to
evaluate the effect of deferasirox treatment on LIC. LIC
was determined by biopsy for all patients at baseline and
following 1 yr of treatment. All measurements were per-
formed in a central laboratory using atomic absorption
spectrometry and were carried out according to stan-
dardized procedures. The primary efﬁcacy endpoint was
treatment success, deﬁned as a reduction in LIC of
‡3m gF e⁄g dw after 1 yr of treatment with deferasirox
if a patient’s baseline LIC was ‡10 mg Fe⁄g dw or a ﬁnal
LIC of 1–7 mg Fe⁄g dw if a patient’s baseline LIC was 2
to <7 or ‡7 to <10 mg Fe⁄g dw. Patients with a base-
line LIC of ‡7m gF e⁄g dw had a therapeutic goal of
LIC reduction, whilst in patients with a baseline LIC of
2t o< 7m gF e ⁄g dw, the therapeutic goal was mainte-
nance.
Secondary efﬁcacy endpoints included absolute and
relative reduction in LIC from baseline to study end and
total body iron excretion rate in subgroups deﬁned by
baseline LIC and age; transfusional iron intake and iron
excretion were calculated according to the method previ-
ously described by Cohen et al.(10) Serum ferritin was
assessed at baseline and at every 4 wk as a potential sur-
rogate marker for LIC.
Safety assessments
Safety was evaluated every 4 wk through the monitoring
and recording of all adverse events and serious adverse
events, and routine laboratory testing, including haema-
tology, blood chemistry and urine renal function assess-
ments. Liver specimens were graded by using the Ishak
staging (measures ﬁbrosis score) and grading (measures
necroinﬂammatory score) system (11, 12). Left ventricu-
lar ejection fraction measurements by echocardiogram
scan were also recorded. Physical and sexual develop-
ment were evaluated in paediatric patients using height
standard deviation score (13) (h-SDS) and Tanner stage
assessments respectively.
Statistical methods
For the intent-to-treat (ITT) analysis, all patients who
had been successfully screened and chosen to start study
treatment were included. All patients who received at
least one dose of study medication were included in the
safety population.
The efﬁcacy analysis in this study was based on evalu-
ation of ‘treatment success’ as described previously. Def-
erasirox therapy was considered to be effective if the
treatment success rate was >50% in the ITT population.
The null hypothesis was tested against the alternative
using a t-test at a one-sided alpha level of 0.025 on the
basis of the normal approximation of the binomial distri-
bution. To examine the proportions of patients with a
LIC of <15 mg Fe⁄g dw or serum ferritin
<2500 ng⁄mL at baseline vs. 1 yr respectively, McNe-
mar tests were performed whereby only patients with
non-missing values at both visits were considered.
To demonstrate at an overall one-sided alpha level of
0.025 that the observed success rate is >50%, it was ﬁrst
calculated that 113 evaluable patients would be required
to achieve a study power of 90%. However, in the ITT
population, patients who dropped out of the trial were
considered to be treatment failures so the attenuated
success rate had to be accounted for by recruiting an
estimated target of 250 patients, assuming an expected
dropout rate of between 5% and 10%.
Results
Patient characteristics
Overall, 237 patients were enrolled from six centres: 162
paediatric patients (aged 2 to <16 yr) and 75 adults
(aged ‡16 yr). A total of 233 (98.3%) patients completed
1 yr of treatment (Table 1). Of the four patients who dis-
continued, two patients were lost to follow-up and two
patients died.
Baseline assessments of LIC and serum ferritin demon-
strated that both the children (mean LIC: 17.0 ± 8.5 mg
Fe⁄g dw; median serum ferritin: 3326 ng⁄mL) and adults
(mean LIC: 20.1 ± 10.1 mg Fe⁄g dw; median serum fer-
ritin: 3396 ng⁄mL respectively) enrolled in this study
were primarily heavily iron overloaded despite previous
chelation therapy.
Dose adjustments
All patients started on deferasirox 20 mg⁄kg⁄d, except
for three who started on 10 mg⁄kg⁄d, which was subse-
quently increased to 20 mg⁄kg⁄d based on protocol
amendment. The median (range) average planned defer-
asirox dose was 23.1 (12–29) mg⁄kg⁄d, which patients
received for a median (range) of 52.3 (6–61) wk. Defer-
asirox dose was adjusted in 192⁄237 (81.0%) patients.
Most patients [185⁄237 (78.1%)] underwent dose
increases above the 20 mg⁄kg⁄d starting dose. The most
common dose increase was to 30 mg⁄kg⁄d [136 patients
(57.4%)], while 47 (19.8%) patients increased to
25 mg⁄kg⁄d. The overall median (range) time to any
dose increase was 26 (8–48) wk and the median (range)
time to dose increase from 20 to 30 mg⁄kg⁄d was 24
Efﬁcacy and safety of deferasirox in b-thalassaemia Taher et al.
460
ª 2009 The Authors
Journal compilation 82 (458–465) ª 2009 Blackwell Munksgaard(8–48) wk. Doses were reduced in nine patients (3.8%),
all of which were due to serum creatinine increases.
A similar proportion of children and adults had dose
adjustments: deferasirox dose was adjusted in 129
(79.6%) paediatric patients and 63 (84.0%) adults. The
median (range) time to dose increase in the paediatric
population was 30 (8–48) wk compared with 20 (8–44)
wk in the adult population.
By the end of the study, most patients (75.9%; 55
adults, 125 children) were receiving ‡25 mg⁄kg⁄d defer-
asirox. Forty-seven (19.8%; 12 adults, 35 children)
patients remained on 20 mg⁄kg⁄d deferasirox whilst six
(2.5%, four adults, two children) were receiving
15 mg⁄kg⁄d.
Effect of deferasirox on LIC
The ITT population experienced a statistically signiﬁcant
treatment success rate of 57.0% (95% conﬁdence interval
[CI] 50.7, 63.3; P = 0.016). In the paediatric and adult
populations, the treatment success rate was 57.4% (95%
CI 49.8, 65.0) and 56.0% (95% CI 44.8, 67.2) respec-
tively. Success rates in patients with baseline LIC of 2 to
<7, ‡7 to <10 and ‡10 mg Fe⁄g dw were 72.7%
(16⁄22), 50.0% (13⁄26) and 56.1% (106⁄189) respectively.
In patients whose therapeutic goal was LIC reduction,
a statistically signiﬁcant mean decrease in LIC of
3.8 ± 6.2 mg Fe⁄gd w( P < 0.001) was achieved at
study end (Fig. 1). In patients whose therapeutic goal
was LIC maintenance, levels were maintained at approxi-
mately baseline level (mean overall increase of
0.9 ± 3.8 mg Fe⁄g dw; P = 0.30, post hoc analysis)
(Fig. 1). The mean absolute reduction in LIC from base-
line in the ITT population was 3.4 mg Fe⁄gd w
(P < 0.001; adults: )4.4 ± 6.3 Fe⁄g dw; children:
)2.9 ± 6.1 Fe⁄g dw).
Overall, 41.9% (n = 95) and 61.7% (n = 140) of
patients had a LIC of <15 mg Fe⁄g dw at baseline and
after 1 yr of treatment respectively; this was 44.0%
(n = 70) and 60.1% (n = 97), and 36.8% (n = 25) and
63.2% (n = 43) in paediatric and adult patients respec-
tively (P < 0.0001 in all groups).
Iron balance
Patients received a mean of 16.5 (±4.5) transfusions over
the 1-yr study, receiving an average of 7.4 (±2.1) mL
red blood cells⁄kg per transfusion. Paediatric patients
received an average of 0.360 mL red blood cells⁄kg⁄d,
resulting in an average iron intake of 0.388 mg⁄kg⁄d and
an average iron excretion rate of 0.423 mg⁄kg⁄d. Thus, in
the paediatric population, the iron excretion : iron intake
Table 1 Baseline patient characteristics
Paediatric (n = 162) Adult (n = 75) All patients (n = 237)
Mean age (range), yr 9.5 (2–15) 21.4 (16–42) 13.3 (2–42)
Female : male, n 80 : 82 37 : 38 117 : 120
Race (caucasian : oriental : other), n 59 : 82 : 21 11 : 43 : 21 70 : 125 : 42
1History of hepatitis B, n (%) 3 (1.9) 1 (1.3) 4 (1.7)
1History of hepatitis C, n (%) 44 (27.2) 29 (38.7) 73 (30.8)
Splenectomy, n (%) 46 (28.4) 53 (70.7) 99 (41.8)
Previous chelation therapy, n (%)
Deferoxamine monotherapy 145 (89.5) 42 (56.0) 187 (78.9)
Deferiprone monotherapy 1 (0.6) 4 (5.3) 5 (2.1)
Deferoxamine + deferiprone 16 (9.9) 29 (38.7) 45 (19.0)
Mean no. of years receiving transfusions (SD) 8.6 (3.7) 18.9 (5.3) 11.8 (6.4)
Mean no. of transfusions in previous year prior
to study entry (SD)
15.5 (4.4) 14.3 (3.7) 15.1 (4.2)
Total amount transfused, mL (SD) 5239 (2452) 7332 (2969) 5828 (2766)
Mean baseline LIC, mg Fe⁄g dw (SD) 17.0 (8.5) 20.1 (10.1) 18.0 (9.1)
Median baseline serum ferritin, ng⁄mL (range) 3326 (914–13 338) 3396 (956–25 008) 3356 (914–25 008)
LIC, liver iron concentration; dw, dry weight.
1Investigator-reported patient history.
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Figure 1 Mean change in liver iron concentration (LIC) after 1 yr’s
treatment with deferasirox.
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excreted compared with intake from transfusions. The
adult population had a positive excretion : intake ratio of
1.462. Adults received 0.260 mL red blood cells⁄kg⁄d,
resulting in an average iron intake of 0.281 mg⁄kg⁄d and
iron excretion rate of 0.392 mg⁄kg⁄d.
Effect of deferasirox on serum ferritin
In the ITT population, median serum ferritin decreased by
341 ng⁄mL (range: )9193 to 2835 ng⁄mL) at 52 wk
(Fig. 2). Changes in serum ferritin appeared to parallel
dose increases at around 24 wk in the adult population. A
greater reduction in median serum ferritin was observed in
the adult population than in the paediatric population
during the course of this 1-yr study [adults: )846 ng⁄mL
(range: )9193 to 2071 ng⁄mL); children: )166 ng⁄mL
(range: )5071 to 2835 ng⁄mL)]. Overall, 35.8% (n = 83)
and 40.5% (n = 94) of patients had serum ferritin levels
<2500 ng⁄mL at baseline and after 1 yr of treatment
respectively; this was 36.0% (n = 58) and 34.8%
(n = 56), and 35.2% (n = 25) and 53.5% (n = 38) in
paediatric and adult patients respectively (P = 0.099 in
the overall population and P < 0.0002 in adults).
In patients whose therapeutic goal was reduction (base-
line LIC ‡7m gF e⁄g dw, n = 215), a statistically signiﬁ-
cant median decrease in serum ferritin of 517 ng⁄mL
(P < 0.001) was achieved at study end. In patients whose
therapeutic goal was maintenance (baseline LIC <7 mg
Fe⁄g dw, n = 22), serum ferritin did not change signiﬁ-
cantly from baseline levels (median overall change of
289 ng⁄mL; P = 0.302, post hoc analysis).
Safety
Adverse events were reported by 180 (75.9%) patients
overall, and the pattern of adverse events was compara-
ble between the paediatric and adult populations. The
most commonly reported adverse events, irrespective of
the relationship to deferasirox treatment, included vomit-
ing (11%), inﬂuenza (11%), nausea (8%), skin rash
(8%), abdominal pain (6%) and diarrhoea (6%).
Adverse events judged to be drug-related by the investi-
gator were reported in 105 (44.3%) patients, most of
which were mild to moderate in severity and resolved
without the need for discontinuing treatment. The most
common drug-related adverse events were vomiting, skin
rash, nausea and increased alanine aminotransferase
(Table 2). There were no discontinuations due to drug-
related adverse events after the start of treatment.
Seventeen (7.2%) patients experienced a total of 36
serious adverse events, the most common of which were
cholecystitis (1.6% of patients), splenomegaly (0.8%),
cardiac failure (0.8%) and cholelithiasis (0.8%), pyrexia
(0.4%), hypocalcaemia (0.4%) and renal failure (0.4%).
Only one serious adverse event (obstructive jaundice of
moderate severity) was considered by the investigator to
be related to study treatment.
Two deaths from cardiac failure were reported; both
were in adult patients with a history of poor compliance
with all previous medications and neither was considered
by the investigator to be related to study medication.
One of these patients had a history of heart failure and
died on day 269 of the study, while the other patient had a
number of risk factors including atrial ectopics and type
II diabetes and died on day 56 of the study. Serum ferritin
levels in these patients at the time of death were 2193 and
9838 ng⁄mL respectively. Two patients were lost to
follow-up.
Seventy-three patients [30.9%; 45 children (28.0%), 28
adults (37.3%)] had two consecutive serum creatinine
levels >33% above baseline not exceeding the ULN; an
additional six patients [2.5%; 4 children (2.5%), 2 adults
(2.4%)] had two consecutive serum creatinine levels
>33% above baseline and >ULN. Four patients (1.7%)
experienced two consecutive increases in alanine amino-
transferase >10 · ULN; of these three already had
elevated alanine aminotransferase at baseline.
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Figure 2 Median serum ferritin levels and mean deferasirox dose
over the 1-yr study period.
Table 2 Most common (>3%) drug-related adverse events⁄laboratory
abnormalities (n = 237) in all patients
Adverse event⁄
laboratory
abnormalities Frequency (%)
Severity (%)
Mild Moderate Severe
Vomiting 21 (8.9) 20 (8.4) 1 (0.4) –
Skin rash 19 (8.0) 12 (5.1) 7 (3.0) –
Nausea 17 (7.2) 15 (6.3) 2 (0.8) –
Increased alanine
aminotransferase
1
13 (5.5) 8 (3.4) 4 (1.7) 1 (0.4)
Increased serum
creatinine
1
9 (3.8) 9 (3.8) – –
1Assessed as an adverse event by the investigator.
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At baseline, the median (range) Ishak grade in ITT pop-
ulation was 2.0 (0–10) which decreased slightly to 1.0 (0–
9) by the end of the study. In the paediatric and adult
populations, median (range) Ishak grade decreased from
2.0 (0–10) and 1.0 (0–6) to 2.0 (0–9) and 1.0 (0–6) respec-
tively. Mean change in each of three groups was )0.1,
)0.2 and )0.2 respectively.
The median (range) Ishak stage in the ITT, paediatric
and adult populations was 2.0 (0–6), 2.0 (0–6) and 3.0
(0–6) respectively. The mean change from baseline after
1 yr was 0.1 in the ITT population and the paediatric
population and )0.1 in the adult population.
Cardiac function
There was a statistically signiﬁcant increase in mean left
ventricular ejection fraction in the ITT population over
the course of the study, from 65.1 (±7.0) at baseline to
66.8 (±6.7) at week 52 (P = 0.0002). Improvement in
left ventricular ejection fraction appeared to be more
pronounced in paediatric patients, with a mean (±SD)
change from baseline of 2.5 (±8.3) in this population,
compared with 0.4 (±6.8) in adults. There was no signif-
icant relationship between change in left ventricular ejec-
tion fraction vs. baseline serum ferritin (P = 0.45) or
change in left ventricular ejection fraction vs. change in
serum ferritin (P = 0.59).
Growth and development assessments in paediatric
patients
Body growth progressed normally in all paediatric
patients (Fig. 3). Height comparisons with a CDC refer-
ence population (13) indicated that both boys and girls
in this study were initially smaller than the reference
group across all ages. Over the 1-yr study period, the
observed growth as evaluated by changes from baseline
in h-SDS showed growth improvements (>0.5 SDS) in
18.1% of patients, worsening in growth in 9.4% of
patients, and no change from baseline in 72.5% of
patients. In this population, girls aged 12 to <16 yr
showed a notable improvement in growth, with 66.7% of
this cohort exhibiting a net increase in h-SDS (25% per-
centile or ﬁrst quartile = )0.06). Sexual development, as
measured by Tanner stage assessments, also progressed
normally.
Discussion
The ESCALATOR trial conducted in the Middle East is
the ﬁrst study to evaluate the efﬁcacy and safety of defer-
asirox exclusively in patients who were previously che-
lated with deferoxamine and⁄or deferiprone. It conﬁrms
the efﬁcacy and safety of deferasirox in thalassaemia
patients reported from a large randomized controlled
study (6). Enrolled patients were characterized by a very
high iron burden despite the previous chelation therapy.
Mean LIC and median serum ferritin levels at baseline
were above thresholds associated with signiﬁcant nega-
tive outcomes (>15 mg Fe⁄g dw and >2500 ng⁄mL
respectively), putting these patients at high risk for car-
diac complications and death (14, 15).
According to prospectively deﬁned criteria, the reduc-
tion or maintenance in iron burden achieved by patients
receiving deferasirox in this study translated into a statis-
tically signiﬁcant treatment success rate of 57.0%
(P = 0.016), which is in-line with previous observations
(6). In patients whose therapeutic goal was LIC reduc-
tion, a statistically signiﬁcant mean decrease in LIC of
3.8 mg Fe⁄gd w( P < 0.001) and serum ferritin of
517 ng⁄mL (P < 0.001) was achieved at study end.
Reducing LIC and serum ferritin in heavily iron-over-
loaded patients is essential for improving patient out-
comes (16, 17). In patients whose therapeutic goal was
LIC maintenance, LIC and serum ferritin levels were
maintained around baseline. As most of these primarily
heavily iron-overloaded patients did not receive a dose
increase to ‡25 mg⁄kg⁄d until more than halfway
through the 1-yr study, further decline in LIC and serum
ferritin is expected with continued use of deferasirox
treatment at a higher dose.
These data highlight the importance of timely deferasi-
rox dose adjustments based on serum ferritin levels and
transfusional iron intake to ensure patients achieve their
therapeutic goal of maintenance or reduction in iron bur-
den. Dose increases to 25 or 30 mg⁄kg⁄d were required
in 78% of patients because they had not achieved their
target reduction in iron burden. This is in line with previ-
ous studies demonstrating that a 20 mg⁄kg⁄d starting
dose of deferasirox may not be sufﬁcient to maintain or
signiﬁcantly reduce LIC and serum ferritin in heavily
Figure 3 Absolute change from baseline in height standard deviation
score in paediatric patients.
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study, although it is often adequate as a maintenance
dose in less heavily transfused and iron-overloaded
patients.(4–7) Furthermore, as dose adjustments occurred
at a median of 24 wk the effect of deferasirox on LIC
and serum ferritin at 52 wk may not reﬂect the full effect
of receiving optimal doses of deferasirox for an extended
period. An ongoing 2-yr extension phase of the ESCA-
LATOR study is currently evaluating the efﬁcacy of
these optimal doses of deferasirox based on monthly
serum ferritin measurements.
Reductions in serum ferritin levels and LIC were not
as pronounced in the paediatric population as in the
adult population. This may be because of a higher trans-
fusional iron intake of children compared with adults
(approximately 30% higher blood transfusions, 0.360 mL
red blood cells⁄kg⁄d vs. 0.260 mL red blood cells⁄kg⁄d),
and hence a higher iron intake (0.388 mg⁄kg⁄d vs.
0.281 mg⁄kg⁄d). There was also a longer median time to
dose increases in the paediatric population (30 wk vs.
20 wk in adults). In addition, previous pharmacokinetic
evaluation of deferasirox has shown that the exposure to
deferasirox is lower in children than in adults.(4–6)
Whether the differing efﬁcacy results between the paedi-
atric and adult population in this study are due to
under-dosing, transfusional iron intake, the pharmacoki-
netic properties of deferasirox or the combination of
these factors may be further elucidated during the exten-
sion phase. Further analyses evaluating the most appro-
priate deferasirox dosing strategy in paediatric patients
would be of value, including chelation-naı¨ve patients and
those switching from other chelation therapies.
Deferasirox was generally well tolerated with a man-
ageable safety proﬁle over the course of the study. The
adverse events observed in this 1-yr study were consistent
with previous observations in patients with b-thalassae-
mia (4–6). There were no discontinuations due to drug-
related adverse events, and no progressive increases in
serum creatinine or liver transaminases. In particular,
increased doses in the paediatric population did not
result in any notable toxicity, and physical and sexual
development progressed normally, showing signiﬁcant
improvement in adolescent girls. Growth retardation and
hypogonadism remain signiﬁcant clinical problems in
adolescent patients with b-thalassaemia despite hyper-
transfusion and regular chelation therapy; these are
encouraging results for a heavily transfused population
(18, 19). The longer-term safety proﬁle of deferasirox in
these patients will be further assessed during the exten-
sion phase.
The risk of cardiac complications and early death are
greatly increased in patients with b-thalassaemia who are
heavily iron overloaded. Previous preliminary data
(reported as an abstract) in patients with both decreased
and normal baseline T2* values who were treated with
deferasirox demonstrated an improvement in myocardial
T2* after 1 yr of treatment; this improvement was main-
tained for 2 yr (20). In ESCALATOR, a statistically sig-
niﬁcant improvement in left ventricular ejection fraction
was observed by week 52, suggesting a positive effect of
deferasirox on cardiac function.
In conclusion, this study conﬁrms previous observa-
tions in patients with b-thalassaemia (6). With appropri-
ate dosing deferasirox controlled iron levels in this
difﬁcult-to-treat population of patients who were primar-
ily heavily iron overloaded despite previous chelation
with deferoxamine and⁄or deferiprone. The efﬁcacy of
deferasirox was dependent on transfusional intake and
optimal dose, highlighting the importance of timely dose
adjustment in order to achieve clinical goals. Deferasirox
was generally well tolerated with no new adverse events
when compared with the deferasirox registration trials.
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Kusai Al Zir: National Thalassemia Center, Damascus,
Syrian Arab Republic.
Shahina Daar: Sultan Qaboos University, Muscat,
Oman.
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conﬁrm the accuracy of the data reported.
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